EUVIMEDEUVIMED entdecken
Crossref

Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)

CDA-AMC

Canadian Journal of Health Technologies · 05.03.2026 · 6 (3)

DOI: 10.51731/cjht.2026.1372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 05.03.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses nivolumab (Opdivo), 40 mg/4 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL), and ipilimumab (Yervoy), 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL). Indication: Opdivo (nivolumab), in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Zitieren

APA

CDA-AMC (2026). Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy). Canadian Journal of Health Technologies, 6(3). https://doi.org/10.51731/cjht.2026.1372

Vancouver

CDA-AMC. Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy). Canadian Journal of Health Technologies. 2026;6(3). doi:10.51731/cjht.2026.1372

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Nivolumab Plus Ipilimumab (Opdivo Plus Yervoy)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {3},
  doi = {10.51731/cjht.2026.1372}
}
Kostenlos starten →